品牌咨询
联系方式
公司地址
苏州工业园区生物纳米园A4#216
联系电话
4000-520-616 / 18915418616
传真号码
0512-67156496
电子邮箱
info@ebiomall.com
公司网址
https://www.ebiomall.com

MedKoo Biosciences/VE-822 (VX-970)/406258/5g

价格
¥129000.00
货号:406258-5g
浏览量:13
品牌:MedKoo
服务
全国联保
正品保证
正规发票
签订合同
商品描述
VE-822, also known as VX-970 or Berzosertib, is an potent ATR inhibitor. VE-822 inhibited ATR in vitro and in vivo. VE-822 decreased maintenance of cell-cycle checkpoints, increased persistent DNA damage and decreased homologous recombination in irradiated cancer cells. VE-822 decreased survival of pancreatic cancer cells but not normal cells in response to XRT or gemcitabine. VE-822 markedly prolonged growth delay of pancreatic cancer xenografts after XRT and gemcitabine-based chemoradiation without augmenting normal cell or tissue toxicity. These findings support ATR inhibition as a promising new approach to improve the therapeutic ration of radiochemotherapy for patients with PDAC.

MedKoo Cat#: 406258
Name: VE-822 (VX-970)
CAS#: 1232416-25-9
Chemical Formula: C24H25N5O3S
Exact Mass: 463.16781
Molecular Weight: 463.55
Elemental Analysis: C, 62.18; H, 5.44; N, 15.11; O, 10.35; S, 6.92


Synonym: VE822; VE-822; VE 822; VX970; VX-970; VX 970; Berzosertib

IUPAC/Chemical Name: 5-(4-(isopropylsulfonyl)phenyl)-3-(3-(4-((methylamino)methyl)phenyl)isoxazol-5-yl)pyrazin-2-amine.

InChi Key: JZCWLJDSIRUGIN-UHFFFAOYSA-N

InChi Code: InChI=1S/C24H25N5O3S/c1-15(2)33(30,31)19-10-8-18(9-11-19)21-14-27-24(25)23(28-21)22-12-20(29-32-22)17-6-4-16(5-7-17)13-26-3/h4-12,14-15,26H,13H2,1-3H3,(H2,25,27)

SMILES Code: NC1=NC=C(C2=CC=C(S(=O)(C(C)C)=O)C=C2)N=C1C3=CC(C4=CC=C(CNC)C=C4)=NO3


Technical Data

Appearance:
Yellow solid powder

Purity:
>98% (or refer to the Certificate of Analysis)

Certificate of Analysis:
View CoA: previous batch: lot#BBC20130911
View CoA: previous batch, lot#SSC40215
View CoA: current batch, Lot#S7S05C02

QC Data:
View QC data: previous batch, lot#BBC20130911
View QC data: previous batch, lot#SSC40215
View QC data: current batch, Lot#S7S05C02

Safety Data Sheet (MSDS):
View Material Safety Data Sheet (MSDS)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility:
Soluble in DMSO, not in water

Shelf Life:
>2 years if stored properly

Drug Formulation:
For in vivo study, VE-822 can be formulated in DMSO. For the in vivo studies, VE-822 was dissolved in 10% Vitamin E d-alpha tocopheryl polyethylene glycol 1000 succinate and administered by gavage, in 200μl.

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

Harmonized System Code:
293490


Additional Information

  
 
 
 


References

1: Fokas E, Prevo R, Pollard JR, Reaper PM, Charlton PA, Cornelissen B, Vallis KA, Hammond EM, Olcina MM, Gillies McKenna W, Muschel RJ, Brunner TB. Targeting ATR in vivo using the novel inhibitor VE-822 results in selective sensitization of pancreatic tumors to radiation. Cell Death Dis. 2012 Dec 6;3:e441. doi: 10.1038/cddis.2012.181. PubMed PMID: 23222511; PubMed Central PMCID: PMC3542617.

我国旅美科学家陈清奇博士创立的MedKoo美帝药库医药公司目前正在建立全球第一个小分子抗癌药库。 MedKoo是一家以研发、生产和销售小分子抗癌化合物为主的医药科技公司。 业务范围 为全球所有从事抗癌药物研究和开发的制药公司,高校,研究院所,政府相关机构提供与抗癌药物分子相关的产品、试剂和技术服务。 技术核心 以药物化学合成技术为核心,密切结合全球抗癌新药研发领域中的新技术、新理论、新趋势和新的发展方向,不断推出抗癌化合物新品种。 建造目标 MedKoo美帝药库的目标是:建成全球最大的小分子抗癌药库 ,品种最多最全、质量最好最可靠。美帝药库的宗旨是:客户第一;质量第一;信誉第一;创新第一。